Trial Profile
A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs CT 1812 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms SPARC
- Sponsors Cognition Therapeutics
- 06 Mar 2024 According to a Cognition Therapeutics media release, presenting results of proteomic and correlation analyses in posters at the AD/PD 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal).
- 04 Jan 2024 According to a Cognition Therapeutics media release, manuscript of the complete SPARC results which has been accepted for publication in the journal, Alzheimer's Research & Therapy.
- 23 May 2023 According to a Cognition Therapeutics media release, the company has released its fifth "Conversations" video podcast, a review and interactive discussion of Cognition's CT1812 biomarker results presented at AD/PD™ 2023, the Alzheimer's & Parkinson's Diseases Conference. The company has presents findings from an unbiased proteomic analysis of combined datasets from completed Phase 1b SPARC study.